In the STEP 1 clinical trial (NEJM, 2021), participants on semaglutide 2.4 mg lost an average of 14.9% of body weight at 68 weeks (about 33.6 lbs from a 232 lb average baseline) vs 2.4% with placebo
Research from Nature Metabolism shows that beta-arrestin1, a protein that normally limits the insulin response to GLP-1, does not limit the insulin response to GIP or tirzepatide
GLP1s delay gastric emptying which causes food to sit in the stomach for longer periods of time, which triggers nausea, says Micheal Currier, PA-C, The other mechanism resides in the central nervous system and is due to how the medication activates GLP-1 receptors in the area of the brain that controls nausea and vomiting, which then leads to an increase in nausea. How common is nausea on GLP-1 drugs
Semaglutide was initially FDA-approved under the brand name Ozempic for treating type 2 diabetes in adults in Grapevine/Southlake, TX
The entire semaglutide dose escalation fits neatly within a single syringe